The ICONIC-LEAD Trial Design of Icotrokinra vs Placebo

Patients with moderate to severe psoriasis achieved unprecedented oral treatment outcomes in the ICONIC-LEAD pivotal studies comparing icotrokinra with placebo. Approximately three-quarters of patients progressed from moderate to severe disease at baseline to clear or almost clear skin at 24 weeks, representing efficacy levels not previously observed with oral psoriasis treatments. The studies included both adults and adolescents 12 years and older, providing comprehensive efficacy data across age groups most affected by psoriasis.

The pivotal trial program demonstrated consistent, reproducible efficacy data across multiple studies, providing patients with confidence in treatment reliability and effectiveness. Patients achieved remarkable response rates with safety profiles similar to placebo, addressing key concerns about oral medication tolerability and long-term use. The inclusion of adolescent patients from initial phase 3 studies represents an advancement for younger individuals seeking effective oral treatment options without waiting years for pediatric-specific trials.

Clinical trial results establish icotrokinra as fulfilling critical unmet needs for patients seeking convenient oral therapy with superior efficacy, excellent safety, and favorable tolerability. Patients now have potential access to oral treatment that delivers a depth of response previously unavailable outside biologic therapy, combined with ease of use that supports long-term adherence. The robust clinical trial program provides patients and health care providers with comprehensive data supporting treatment decisions for moderate to severe psoriasis across diverse patient populations.